fbpx Skip to main content

Partner Day with Novo Nordisk

When:

March 23, 2020 5:00 pmMarch 23, 2020 7:00 pm (PDT)

Where:

Mission Bay Conference Center at UCSF
1675 Owens Street
San Francisco, California 94143

Registration Closed


March 23rd, senior leaders from Novo Nordisk will be in San Francisco to meet with local biotech companies, academic institutions, research organizations, venture capital firms, and the local Bay Area Life Sciences community. Throughout the day, Novo Nordisk will cover their therapeutic areas of focus for innovation partnering along with an interactive panel discussion. A complimentary networking reception will follow the program.

At Novo Nordisk, we are driving change to defeat diabetes and other serious chronic conditions. Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: rare bleeding disorders, growth hormone related disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 42,700 people in 79 countries and markets its products in more than 170 countries.

The Mission of Novo Nordisk R&D is to develop innovative therapeutic proteins for chronic illnesses. Scientific collaborations with strategic partners in industry and academia are essential part of this pursuit for sustainable innovation. In addition, Novo Nordisk explores commercial partnerships on a global scale to bring innovative therapies to patients.

Partner Day Agenda

  • 5:00pm – 5:30pm: Networking & Registration
  • 5:30pm – 5:45pm Novo Nordisk Corporate Overview & Brief Presentation
    • Welcome
    • Corporate Overview
    • Therapeutic Area Overview
    • Partnering with Novo Nordisk
  • 5:45pm – 7:00pm: Networking Reception

Areas of Focus:


Diabetes:
  • Next generation insulins and GLP-1 receptor antagonists with additional benefits beyond glucose control e.g., weight loss or co-morbidities
  • Novel compounds that show insulin sensitization, improve insulin resistance and/or glucose recognition with added benefits such as weight loss and co-morbidities
  • Compounds that have improved effects on Beta cell health
  • Oral peptides and novel protein delivery platforms
  • Novel approaches to treating Type I Diabetes
Obesity:
  • Novel compounds that effect appetite regulation and energy expenditure
  • Novel compounds that show improvement in lean body mass through fat loss
  • Novel compounds that address co morbidities such as diabetes, cardiovascular disease and /or NASH
  • Validated biochemical pathways and mechanisms that cause a significant weight loss of greater than 15%

Other Chronic Diseases:
  • NASH-Novel compounds that treat fibrotic and inflammatory disease aspects of metabolic associated disease
  • Atherosclerosis- Novel compounds that have the potential to address risk in patients with high CVD risk in addition to other cholesterol lowering therapies (e.g., statins)
  • Chronic Heart Failure- Novel compounds with the potential to add significant benefit for patient with systolic or diastolic dysfunction
  • Chronic Kidney Disease- Novel compounds that treat specific aspects of fibrosis and inflammation associated with this disease
  • Novel compounds that treat Hemophilia, focusing on novel bypassing agents, long acting coagulation factors and cell/gene therapy approaches

Other Focus Areas:
  • Cell therapies (stem cells), for serious chronic diseases
  • Novel cell encapsulation technologies and other technologies related to the design, production and application of stem cell derived therapies
  • Platforms for RNA-based therapies
  • Peptide and protein technology platforms (e.g., expression, purification and modification of proteins and peptides)
  • Exosomes and cell penetrating technologies

How to Participate: 1:1 Meetings:

If you are working in any of the areas of interest outlined above please submit a one-page executive summary or company overview including detailed descriptions of any program(s) you would like to discuss to Oscar Rodarte, Manager of Capital Development, at orodarte@biocom.org as soon as possible, but no later, than Monday, March 2nd for consideration.

Please note that registering for the event does not guarantee a meeting with the Novo Nordisk business development team; you must submit an application. Selected companies will be notified directly.


In Partnership With:

User-added image

Price of Admission

Biocom Member

Today’s Price: 0

Important Dates

Amount

Registration before

Registration before

Registration before

Registration cost

0

Refund before 2020-03-23

0

Refund before

Refund Before

Biocom Non-Member

Today’s Price: 0

Important Dates

Amount

Registration before

Registration before

Registration before

Registration cost

0

Refund before 2020-03-23

0

Refund before

Refund Before

  • Novo Nordisk Team
    List of Key Senior Scientists Participating:

    Stem Cell Track
    Dr. Jacob Petersen PhD 
    Corporate Vice President
    Global Head Stem Cell Research and Development

    Diabetes/CVD/CKD Track
    Dr. Karin Conde-Knape PhD 
    Corporate Vice President
    Global Head Diabetes, Cardio-Renal Translational Research

    Obesity/Liver Disease Track
    Dr. Mads Tang-Christensen MD, PhD 
    Corporate Vice President
    Global Head Obesity and Liver Disease Research

    Machine Learning/Artificial Intelligence Track
    Dr. Alan Shaw PhD
    Vice President
    Head of Computational Research

    Protein Technologies Track
    Dr. Brian Vandah PhD 
    Corporate Vice President
    Head of Recombinant Technologies

    Dr. Jesper Lau PhD 
    Vice President
    Head Research Chemistry
     

Registration Closed